Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.33 as of Sunday, July 26, 2026.
Forward PE Ratio (14.33) = Close Price ($656.01) / Consensus Forward EPS ($45.77)
FORWARD PE RATIO
14.33
SECTOR MEDIAN · HEALTHCARE
18.38
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-22.06%
vs the sector median at left
Regeneron Pharmaceuticals, Inc.
Market Cap
$67.58B
Forward PE Ratio
14.33
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | $67.58B | 14.33 |
| Boston Scientific Corporation (BSX)vs › | $65.77B | 13.18 |
| Cencora, Inc. (COR)vs › | $60.29B | 17.43 |
| Cigna Corporation (CI)vs › | $76.60B | 9.51 |
| Becton, Dickinson and Company (BDX)vs › | $56.65B | 12.40 |
| Cardinal Health, Inc. (CAH)vs › | $53.41B | 21.16 |
| Elevance Health Inc. (ELV)vs › | $81.91B | 13.93 |
| HCA Healthcare, Inc. (HCA)vs › | $84.78B | 12.75 |
| Edwards Lifesciences Corporation (EW)vs › | $47.58B | 27.52 |
| Humana Inc. (HUM)vs › | $46.74B | 43.48 |
Trailing P/E
16.0
reported TTM EPS
Forward P/E
14.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $45.77 implies +11.5% EPS growth vs the reported trailing $41.04.
At today's $656.01 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $45.77 | $40.81 – $49.84 | 15 | 14.3x |
| 2027-12-31 | $53.53 | $29.61 – $63.82 | 9 | 12.3x |
| 2028-12-31 | $60.98 | $50.37 – $71.64 | 7 | 10.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
